ES2177592T3 - Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos. - Google Patents

Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.

Info

Publication number
ES2177592T3
ES2177592T3 ES95110445T ES95110445T ES2177592T3 ES 2177592 T3 ES2177592 T3 ES 2177592T3 ES 95110445 T ES95110445 T ES 95110445T ES 95110445 T ES95110445 T ES 95110445T ES 2177592 T3 ES2177592 T3 ES 2177592T3
Authority
ES
Spain
Prior art keywords
biocompatible
proteinic
medicines
administration
absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95110445T
Other languages
English (en)
Inventor
Christian Grandfils
Robert Jerome
Nicole Nihant
Philippe Teyssie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
European Economic Community
Original Assignee
European Economic Community
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by European Economic Community filed Critical European Economic Community
Application granted granted Critical
Publication of ES2177592T3 publication Critical patent/ES2177592T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINACION DE POLIMEROS OBTENIBLE MEDIANTE UN PROCESO QUE INCLUYE LAS SIGUIENTES FASES DE MEZCLA: - UN POLIMERO BIOCOMPATIBLE CAPAZ DE FORMAR NANOPARTICULAS Y - UN AGENTE DE INTERACCION BIOCOMPATIBLE PARA CONSEGUIR LA COMBINACION POLIMERICA SUCEPTIBLE DE SER ADMINISTRADA CON EL MEDICAMENTO CUYO AGENTE INTERACTUANTE ES CAPAZ DE PRESERVAR LA ACTIVIDAD DEL MEDICAMENTO A ADMINISTRAR Y EN LA CUAL EL AGENTE INTERACTUANTE ES CAPAZ DE CONTROLAR LA DISTRIBUCION DEL MEDICAMENTO A ADMINISTRAR.
ES95110445T 1995-07-05 1995-07-05 Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos. Expired - Lifetime ES2177592T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95110445A EP0752245B1 (en) 1995-07-05 1995-07-05 Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery

Publications (1)

Publication Number Publication Date
ES2177592T3 true ES2177592T3 (es) 2002-12-16

Family

ID=8219415

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95110445T Expired - Lifetime ES2177592T3 (es) 1995-07-05 1995-07-05 Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.

Country Status (10)

Country Link
US (1) US5962566A (es)
EP (1) EP0752245B1 (es)
JP (1) JP3486417B2 (es)
AT (1) ATE217792T1 (es)
CA (1) CA2226166C (es)
DE (1) DE69526787T2 (es)
DK (1) DK0752245T3 (es)
ES (1) ES2177592T3 (es)
PT (1) PT752245E (es)
WO (1) WO1997002022A1 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU752802C (en) 1997-11-14 2006-04-13 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
US7651875B2 (en) * 1998-06-08 2010-01-26 Borealis Technical Limited Catalysts
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
CN1406140A (zh) 2000-02-28 2003-03-26 吉倪塞思公司 纳米胶囊包封***与方法
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
EP1306127B2 (en) * 2001-10-26 2011-09-07 OctoPlus PolyActive Sciences B.V. Method for the preparation of purified microparticles
WO2003043586A2 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
ATE466281T1 (de) * 2002-05-07 2010-05-15 Univ New York State Res Found ßHIGH THROUGPUTß METHODE, UM BIOMOLEKÜLANLIEFERUNG FORMULIERUNGEN ZU KENNZEICHNEN
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
EP1537846A1 (en) * 2002-09-11 2005-06-08 Tanabe Seiyaku Co., Ltd. Process for the production of microspheres and unit therefor
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
US6780896B2 (en) * 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
ES2226567B1 (es) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela Nanoparticulas de acido hialuronico.
ES2232287B1 (es) * 2003-07-04 2006-11-01 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de derivados polioxietilenados.
WO2005035606A1 (en) * 2003-10-10 2005-04-21 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US7837663B2 (en) 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
US7879350B2 (en) 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
ES2246695B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
CA2571899A1 (en) * 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US7332159B2 (en) * 2004-09-30 2008-02-19 Board Of Regents Of The University Of Nebraska Method and composition for inhibiting reperfusion injury in the brain
US8846607B2 (en) * 2004-10-29 2014-09-30 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
US8263105B2 (en) 2004-12-01 2012-09-11 Tyco Healthcare Group Lp Biomaterial drug delivery and surface modification compositions
CA2526541C (en) 2004-12-01 2013-09-03 Tyco Healthcare Group Lp Novel biomaterial drug delivery and surface modification compositions
WO2006112477A1 (ja) * 2005-04-20 2006-10-26 Taiho Pharmaceutical Co., Ltd. アジュバントとしてのポリアミノ酸
KR100718329B1 (ko) * 2005-09-08 2007-05-14 광주과학기술원 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법
US20070248675A1 (en) * 2005-09-08 2007-10-25 Gwangju Institute Of Science And Technology Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof
US7977103B2 (en) 2006-04-20 2011-07-12 Kimberly-Clark Worldwide, Inc. Method for detecting the onset of ovulation
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20080102127A1 (en) * 2006-10-26 2008-05-01 Gao Hai Y Hybrid lipid-polymer nanoparticulate delivery composition
EP2078052B1 (en) * 2006-10-31 2010-07-28 Surmodics Pharmaceuticals, Inc. Spheronized polymer particles
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
KR101005562B1 (ko) 2008-05-01 2011-01-05 한국생명공학연구원 난용성 약물을 함유하는 균일한 크기의 고분자 나노입자제조방법
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
WO2010033878A2 (en) 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
CA2756072A1 (en) * 2009-03-30 2010-10-14 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US8758323B2 (en) 2009-07-30 2014-06-24 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
JP5796275B2 (ja) * 2010-06-02 2015-10-21 セイコーエプソン株式会社 分光測定器
CN103221070B (zh) 2010-08-30 2019-07-12 哈佛大学校长及研究员协会 用于狭窄病变和溶解血栓疗法的切变控制释放
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
ES2640648T3 (es) 2013-09-16 2017-11-03 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso
WO2015160794A1 (en) * 2014-04-14 2015-10-22 Ecosynthetix Ltd. Bio-based nanoparticle and composite materials derived therefrom
CA2959660A1 (en) 2014-09-03 2016-03-10 Genesegues, Inc. Therapeutic nanoparticles and related compositions, methods, and systems
US10548881B2 (en) 2016-02-23 2020-02-04 Tarveda Therapeutics, Inc. HSP90 targeted conjugates and particles and formulations thereof
US11654117B2 (en) * 2016-11-03 2023-05-23 Case Western Reserve University Melt processed viral nanoparticle constructs
US20230355540A1 (en) 2020-09-29 2023-11-09 Oxford University Innovation Limited Stroke treatment
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
AU610594B2 (en) * 1987-04-16 1991-05-23 Christian Bindschaedler Process for preparing a powder of water-insoluble polymer which can be redispersed in a liquid phase, the resulting powder and utilization thereof
FR2660556B1 (fr) * 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FR2678168B1 (fr) * 1991-06-28 1993-09-03 Rhone Poulenc Rorer Sa Nanoparticules ayant un temps de capture par le dysteme reticulo endothelial allonge.
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
ES2034891B1 (es) * 1991-08-08 1993-12-16 Cusi Lab Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
ES2078175B1 (es) * 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.

Also Published As

Publication number Publication date
DE69526787D1 (de) 2002-06-27
EP0752245B1 (en) 2002-05-22
JP3486417B2 (ja) 2004-01-13
PT752245E (pt) 2002-09-30
JPH11504655A (ja) 1999-04-27
CA2226166A1 (en) 1997-01-23
WO1997002022A1 (en) 1997-01-23
US5962566A (en) 1999-10-05
EP0752245A1 (en) 1997-01-08
CA2226166C (en) 2001-05-08
ATE217792T1 (de) 2002-06-15
DK0752245T3 (da) 2002-09-09
DE69526787T2 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
ES2177592T3 (es) Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.
GT199900151A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial.
FR2771004B1 (fr) Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
MX9301823A (es) Composicion para el suministro de liberacion controlado de un agente biologicamente activo.
AU6764390A (en) Pharmaceutical granules and drug dosage units made therefrom
NO923769L (no) System for iontoforetisk tilfoersel av et medikament
GEP20043216B (en) Orally Administered Controlled Drug Delivery System
BRPI0410956A (pt) pelìculas com base em óxido de polietileno e sistemas de liberação de droga feitos delas
DE69229566D1 (de) Zusammensetzung und verfahren zur freisetzung von arzneistoffen
ES2094781T3 (es) Composicion farmaceutica de microparticulas con liberacion controlada y su proceso de preparacion.
ES2177637T3 (es) Medicamentos para el tratamiento de la restenosis, que comprenden polimeros liberadores de oxido nitrico.
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
MX9301821A (es) Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo.
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
IS1858B (is) Aðferð til að framleiða lyfjablöndu á formi smápilla til að meðhöndla þarmabólgur
BG95911A (bg) Лекарствена парентерална форма с депо действие
GR3022033T3 (en) Transdermal system with stepwise drug release, and its use in local or systemic cosmetic administration
UA39884C2 (uk) Таблетка на основі клодронової кислоти, спосіб її одержання та спосіб лікування остеопорозу
KR910005858A (ko) 지방산 요법
ATE206911T1 (de) Feste arzneimittelform mit polymerem material verteiltem wirkstoff
KR890007728A (ko) 진통제 제조방법
Mendels et al. Antidepressant effects of desipramine administered in two dosage schedules.
HU9600670D0 (en) Dextrane esters, process for producing them and their use for encasing and encapsulating medicaments
Valentine et al. Low-Molecular-Weight Heparin in the Initial Treatment of Proximal Deep Vein Thrombosis
Paprocki Workshop B